Treatment of Severe Bacterial Conjunctivitis
For severe bacterial conjunctivitis, initiate empiric treatment with topical fluoroquinolones (such as gatifloxacin, moxifloxacin, or ofloxacin) while obtaining conjunctival cultures and Gram staining immediately to guide subsequent therapy. 1
Initial Diagnostic Steps
- Obtain conjunctival cultures and Gram staining before starting antibiotics, particularly when gonococcal infection is suspected, as this will guide definitive therapy 1, 2
- Examine for copious purulent discharge, marked inflammation, pain, and swollen preauricular or submandibular lymph nodes to confirm severe bacterial infection 1
- Measure visual acuity and perform slit-lamp biomicroscopy to assess for corneal involvement, which requires immediate ophthalmology referral 2
Empiric Antibiotic Selection
Fluoroquinolones are the preferred first-line empiric choice due to their broad-spectrum coverage against common pathogens including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. 1, 3
Specific Fluoroquinolone Options:
- Gatifloxacin 0.5%: Instill one drop every 2 hours while awake (up to 8 times) on Day 1, then one drop 2-4 times daily on Days 2-7 4
- Moxifloxacin 0.5% or ofloxacin 0.3%: Alternative fluoroquinolones with similar efficacy 3, 2
Alternative Agents:
- Aminoglycosides (tobramycin or gentamicin): Effective alternatives when fluoroquinolones should be reserved or are unavailable 1, 2
- These agents provide good coverage but should be administered frequently (every 2-4 hours initially) 2
Pathogen-Specific Considerations
Methicillin-Resistant Staphylococcus aureus (MRSA):
- MRSA has been isolated with increasing frequency from bacterial conjunctivitis cases 1, 5
- Culture results should guide therapy; compounded topical vancomycin may be required for confirmed MRSA infections 1, 2
- Fluoroquinolone resistance is common in MRSA, making culture-directed therapy essential 3
Neisseria gonorrhoeae:
- Systemic antibiotic therapy is mandatory—topical therapy alone is insufficient 1, 2
- Add frequent saline lavage to promote comfort and reduce inflammation 2
- Requires daily follow-up until complete resolution 1
- Consider hospitalization for severe cases 2
Chlamydia trachomatis:
- Systemic antibiotic therapy is required—topical therapy alone is inadequate 1, 2
- Oral azithromycin (single dose) or tetracycline (7 days for adults) are recommended 3
Follow-Up Protocol
- Non-gonococcal severe cases: Return in 3-4 days if no improvement, with interval history, visual acuity measurement, and slit-lamp examination 1, 2
- Gonococcal cases: Daily follow-up is mandatory until complete resolution 1
- If no improvement after 3-4 days, reassess diagnosis, review culture results, and consider alternative pathogens or resistance 2, 5
Critical Pitfalls to Avoid
- Do not use topical corticosteroids unless under close ophthalmologic supervision, as they may prolong bacterial shedding and worsen infection 2
- Reserve fluoroquinolones for severe infections to preserve their effectiveness and minimize resistance development 1, 5
- Never rely on topical therapy alone for gonococcal or chlamydial conjunctivitis—systemic treatment is essential 1, 2
- Do not allow contact lens wear during active infection or treatment, as this increases risk of complications 4
Immediate Ophthalmology Referral Indications
Refer immediately for any of the following 1, 2:
- Visual loss or decreased visual acuity
- Moderate to severe eye pain
- Corneal involvement (infiltrate, ulceration, or opacity)
- Conjunctival scarring
- Lack of response to therapy after 3-4 days
- Recurrent episodes
- Suspected gonococcal infection
Antibiotic Resistance Considerations
- Methicillin resistance occurs in approximately 42% of staphylococcal isolates, with high concurrent fluoroquinolone resistance 3
- Individual risk factors for fluoroquinolone resistance include recent fluoroquinolone use, hospitalization, advanced age, and recent ocular surgery 3
- Streptococcus pneumoniae shows the greatest level of resistance to commonly used topical antibiotics 6